Company Description
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.
The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system.
In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases.
It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors.
The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
| Country | United States |
| Founded | 1998 |
| IPO Date | Jun 25, 2015 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 995 |
| CEO | Thomas Burns |
Contact Details
Address: One Glaukos Way Aliso Viejo, California 92656 United States | |
| Phone | 949 367 9600 |
| Website | glaukos.com |
Stock Details
| Ticker Symbol | GKOS |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001192448 |
| CUSIP Number | 377322102 |
| ISIN Number | US3773221029 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Thomas William Burns | Chairman and Chief Executive Officer |
| Joseph E. Gilliam | President and Chief Operating Officer |
| Alex R. Thurman | Senior Vice President and Chief Financial Officer |
| Dr. Tomas Navratil Ph.D. | Chief Development Officer |
| Christopher William Lewis | Vice President of Investor Relations and Corporate Affairs |
| Robert L. Davis J.D. | Senior Vice President, General Counsel and Business Development |
| Diana A. Scherer | Vice President of Compliance and Deputy General Counsel |
| Michele M. Allegretto | Senior Vice President of Human Resources |
| L. Jay Katz FACS, M.D. | Chief Medical Officer |
| Jane E. Rady | Senior Vice President of Corporate Strategy and Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 30, 2025 | 8-K | Current Report |
| Jun 3, 2025 | 8-K | Current Report |
| May 30, 2025 | SD | Form - SD |
| May 14, 2025 | 8-K | Current Report |
| May 1, 2025 | 10-Q | Quarterly Report |
| Apr 30, 2025 | 8-K | Current Report |
| Apr 29, 2025 | SCHEDULE 13G/A | Filing |
| Apr 15, 2025 | ARS | Filing |
| Apr 15, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 15, 2025 | DEF 14A | Other definitive proxy statements |